Related Experiment Videos
Does vancomycine increase aminoglycoside nephrotoxicity?
A Törel Ergür1, B Onarlioglu, Y Günay
1Department of Pediatrics, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey.
Acta Paediatrica Japonica : Overseas Edition
|August 1, 1997
Summary
Vancomycin and amikacin combination therapy for serious infections did not increase kidney damage in rats. This study suggests the combined use of these antibiotics is safe regarding nephrotoxicity.
Area of Science:
- Pharmacology
- Nephrology
- Toxicology
Background:
- Vancomycin and amikacin are crucial for treating Gram-positive bacteremia.
- Both antibiotics possess individual nephrotoxic potential.
- The combined nephrotoxicity of vancomycin and amikacin requires investigation.
Purpose of the Study:
- To evaluate if combined vancomycin and amikacin administration exacerbates nephrotoxicity compared to individual use.
- To assess the impact of combined antibiotic therapy on renal structure and function.
Main Methods:
- A 15-day study involving three groups of rats: combined vancomycin-amikacin, amikacin alone, and a control group.
- Renal tissues examined using light and electron microscopy.
- Serum creatinine and blood urea nitrogen (BUN) levels measured.
Main Results:
- Both amikacin and combined vancomycin-amikacin groups showed glomerular and tubular renal morphological changes.
- Elevated serum creatinine and BUN levels were observed in both treatment groups compared to controls.
- No significant difference in nephrotoxicity was found between the individual amikacin and combined therapy groups.
Conclusions:
- Vancomycin does not appear to potentiate the nephrotoxic effects of amikacin.
- Combined vancomycin and amikacin therapy can be considered safe for use in pediatric bacteremia treatment regarding kidney function.